Suppr超能文献

来自美国医疗记录数据库的银屑病生物疗法相关处方模式。

Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database.

作者信息

Noe Megan H., Shin Daniel B., Doshi Jalpa A., Margolis David J., Gelfand Joel M.

出版信息

J Drugs Dermatol. 2019 Aug 1;18(8):745-750.

Abstract

INTRODUCTION

Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, access to care, and both patient and provider preference. The objective of this study was to use data from electronic health records to understand prescribing patterns associated with biologic therapies for psoriasis and utilization of concomitant non-biologic psoriasis therapies in patients on biologics. METHODS: A retrospective cohort study was performed using OptumInSight’s electronic health records database. Patients were classified as having psoriasis if they had 2 diagnosis codes for psoriasis or 1 diagnosis for psoriasis and a subsequent prescription for a systemic psoriasis therapy or phototherapy on a separate day. Only patients with at least 1 prescription for a biologic medication were included. The time between the first and last prescription in each prescription episode was calculated; at least 1 prescription every 180 days was required to be considered continuous therapy. We also identified a subgroup of patients with prescription episodes of at least 12 months duration in which to evaluate concomitant use of topical medications, phototherapy, and other systemic agents in patients receiving prescriptions for biologics. RESULTS: There were 34,714 eligible psoriasis patients. The median time between first and last prescriptions was 3.3 - 7.0 months, depending on the drug and up to 50% of patients that received a prescription for a biologic medication did not receive a second prescription for the same medication. In a subset of patients with prescription episodes of at least 12 months duration, more than 50% continued to receive prescriptions for topical therapies, most commonly topical steroids. DISCUSSION: Recognition of prescribing patterns associated with biologic medications for psoriasis is important to understand healthcare utilization and improve health systems practices for patients and providers.

摘要

引言

为银屑病患者选择全身治疗方法是一个复杂的过程,这基于多种因素,包括银屑病的严重程度、合并的健康状况、获得治疗的途径以及患者和医疗服务提供者的偏好。本研究的目的是利用电子健康记录中的数据,了解与银屑病生物治疗相关的处方模式以及接受生物制剂治疗的患者同时使用非生物银屑病治疗方法的情况。方法:使用OptumInSight的电子健康记录数据库进行一项回顾性队列研究。如果患者有2个银屑病诊断代码,或者有1个银屑病诊断且随后在另一天开具了全身银屑病治疗或光疗的处方,则将其归类为患有银屑病。仅纳入至少有1次生物药物处方的患者。计算每个处方疗程中第一次和最后一次处方之间的时间;每180天至少有1次处方才能被视为持续治疗。我们还确定了一个处方疗程至少持续12个月的患者亚组,以评估接受生物制剂处方的患者同时使用局部用药、光疗和其他全身药物的情况。结果:有34714名符合条件的银屑病患者。第一次和最后一次处方之间的中位时间为3.3 - 7.0个月,具体取决于药物,并且接受生物药物处方的患者中高达50%没有收到同一种药物的第二次处方。在处方疗程至少持续12个月的患者亚组中,超过50%的患者继续接受局部治疗的处方,最常见的是局部类固醇。讨论:认识与银屑病生物药物相关的处方模式对于了解医疗保健利用情况以及改善针对患者和医疗服务提供者的卫生系统实践非常重要。

相似文献

3
Opioid prescribing in adults with and without psoriasis.
J Am Acad Dermatol. 2020 Dec;83(6):1777-1779. doi: 10.1016/j.jaad.2020.03.080. Epub 2020 Apr 1.
5
Provider and Patient Determinants of Generic Levothyroxine Prescribing: An Electronic Health Records-Based Study.
Ann Pharmacother. 2017 Aug;51(8):640-648. doi: 10.1177/1060028017705393. Epub 2017 Apr 20.
9
Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.

引用本文的文献

1
Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial.
JAMA Dermatol. 2024 Dec 1;160(12):1320-1328. doi: 10.1001/jamadermatol.2024.3897.
2
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective.
J Manag Care Spec Pharm. 2024 Nov;30(11):1226-1238. doi: 10.18553/jmcp.2024.24036. Epub 2024 Jul 27.
5
Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents.
J Allergy Clin Immunol. 2022 Feb;149(2):640-649.e5. doi: 10.1016/j.jaci.2021.07.024. Epub 2021 Jul 31.
6
Veridical Causal Inference using Propensity Score Methods for Comparative Effectiveness Research with Medical Claims.
Health Serv Outcomes Res Methodol. 2021 Jun;21(2):206-228. doi: 10.1007/s10742-020-00222-8. Epub 2020 Oct 20.

本文引用的文献

1
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.
2
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
J Manag Care Spec Pharm. 2018 Dec;24(12):1240-1246. doi: 10.18553/jmcp.2018.24.12.1240.
5
Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):245-253. doi: 10.1111/jdv.14583. Epub 2017 Oct 17.
6
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.
Br J Dermatol. 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665.
7
Biologic drug survival in Israeli psoriasis patients.
J Am Acad Dermatol. 2017 Apr;76(4):662-669.e1. doi: 10.1016/j.jaad.2016.10.033. Epub 2016 Dec 28.
10
Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
J Am Acad Dermatol. 2016 Jun;74(6):1057-1065.e4. doi: 10.1016/j.jaad.2016.01.048. Epub 2016 Mar 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验